The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
Abstract Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.937 |
| _version_ | 1818115440619028480 |
|---|---|
| author | Matthew J. Lawrence Vanessa Evans Janet Whitley Suresh Pillai Phylip R. Williams James Coulson Manju Krishnan Peter Slade Kieron Power Roger H.K. Morris Phillip A. Evans |
| author_facet | Matthew J. Lawrence Vanessa Evans Janet Whitley Suresh Pillai Phylip R. Williams James Coulson Manju Krishnan Peter Slade Kieron Power Roger H.K. Morris Phillip A. Evans |
| author_sort | Matthew J. Lawrence |
| collection | DOAJ |
| description | Abstract Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28 AF without stroke (AF). Pre‐ and post‐anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df, the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF‐S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood’s ability to form stable clots (no change in df). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics. |
| first_indexed | 2024-12-11T04:06:39Z |
| format | Article |
| id | doaj.art-a20d7bd65b524b57863155638c0a89f5 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-12-11T04:06:39Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-a20d7bd65b524b57863155638c0a89f52022-12-22T01:21:30ZengWileyPharmacology Research & Perspectives2052-17072022-04-01102n/an/a10.1002/prp2.937The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarkerMatthew J. Lawrence0Vanessa Evans1Janet Whitley2Suresh Pillai3Phylip R. Williams4James Coulson5Manju Krishnan6Peter Slade7Kieron Power8Roger H.K. Morris9Phillip A. Evans10Welsh Centre for Emergency Medicine Research Swansea Bay University Health Board Swansea UKWelsh Centre for Emergency Medicine Research Swansea Bay University Health Board Swansea UKWelsh Centre for Emergency Medicine Research Swansea Bay University Health Board Swansea UKWelsh Centre for Emergency Medicine Research Swansea Bay University Health Board Swansea UKCollege of Engineering Swansea University Swansea UKSchool of Medicine Cardiff University Cardiff UKStroke Unit Swansea Bay University Health Board Swansea UKStroke Unit Swansea Bay University Health Board Swansea UKPharmacy Department Swansea Bay University Health Board Swansea UKSchool of Applied Science Cardiff Metropolitan University Cardiff UKWelsh Centre for Emergency Medicine Research Swansea Bay University Health Board Swansea UKAbstract Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28 AF without stroke (AF). Pre‐ and post‐anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df, the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF‐S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood’s ability to form stable clots (no change in df). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.https://doi.org/10.1002/prp2.937anticoagulationapixabancerebrovascular diseaseclot microstructuregel point and fractal analysis |
| spellingShingle | Matthew J. Lawrence Vanessa Evans Janet Whitley Suresh Pillai Phylip R. Williams James Coulson Manju Krishnan Peter Slade Kieron Power Roger H.K. Morris Phillip A. Evans The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker Pharmacology Research & Perspectives anticoagulation apixaban cerebrovascular disease clot microstructure gel point and fractal analysis |
| title | The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker |
| title_full | The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker |
| title_fullStr | The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker |
| title_full_unstemmed | The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker |
| title_short | The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker |
| title_sort | effects of apixaban on clot characteristics in atrial fibrillation a novel pharmacodynamic biomarker |
| topic | anticoagulation apixaban cerebrovascular disease clot microstructure gel point and fractal analysis |
| url | https://doi.org/10.1002/prp2.937 |
| work_keys_str_mv | AT matthewjlawrence theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT vanessaevans theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT janetwhitley theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT sureshpillai theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT phyliprwilliams theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT jamescoulson theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT manjukrishnan theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT peterslade theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT kieronpower theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT rogerhkmorris theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT phillipaevans theeffectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT matthewjlawrence effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT vanessaevans effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT janetwhitley effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT sureshpillai effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT phyliprwilliams effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT jamescoulson effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT manjukrishnan effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT peterslade effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT kieronpower effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT rogerhkmorris effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker AT phillipaevans effectsofapixabanonclotcharacteristicsinatrialfibrillationanovelpharmacodynamicbiomarker |